Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Next Previous
X
Search
Trial Profile

A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RBD 1016 (Primary) ; Entecavir
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Suzhou Ribo Life Science

    • Most Recent Events

    • 30 Oct 2023 Status changed from recruiting to completed.
    • 24 Jun 2023 Preliminary results (n=27; As of December 28, 2022) assessing the safety and antiviralactivity of RBD1016 in subjects with chronic HBV infection, presented at the European Association for the Study of the Liver Congress 2023.
    • 24 Apr 2022 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top